Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Odor-No-More is a wholly owned subsidiary of BioLargo, Inc., focused on providing advanced odor control solutions for industrial, municipal, and commercial markets. The company’s core technology, CupriDyne, utilizes a patented iodine-based oxidative chemistry to break down odor-causing compounds and volatile organic compounds (VOCs) at the molecular level. Unlike traditional masking agents, Odor-No-More’s products are designed to eliminate odors safely and effectively without the use of harsh chemicals or fragrances. Its solutions are widely deployed in high-impact environments such as solid waste facilities, wastewater treatment plants, and animal care centers. The company emphasizes sustainability and environmental safety, offering non-toxic alternatives to conventional industrial deodorizers. Through its integration with BioLargo’s broader life sciences platform, Odor-No-More continues to innovate in the field of air quality and environmental remediation.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Odor-No-More.